Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. May 26, 2006Chelsea Therapeutics International, Ltd. • August 14th, 2006 • Biological products, (no disgnostic substances) • New York
Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. EXCLUSIVE LICENSE AGREEMENTSubscription Agreement • August 14th, 2006 • Chelsea Therapeutics International, Ltd. • Biological products, (no disgnostic substances) • England
This Agreement is made effective the 26th day of May, 2006 (hereinafter called the “Effective Date”), by and between Dainippon Sumitomo Pharma Co., Ltd., a Japanese corporation having a place of business at 6-8 Doshomachi 2-chome, Chuo-ku, Osaka 541-0045, Japan (hereinafter called “DSP”), and Chelsea Therapeutics, Inc., a Delaware corporation having a place of business at 13950 Ballantyne Corporate Place, Suite 325, Charlotte, NC 28277, U.S.A. (hereinafter called “Chelsea”). DSP and Chelsea may be referred to herein individually as a “Party” or together, as the “Parties”.
Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDevelopment and Commercialization Agreement • August 14th, 2006 • Chelsea Therapeutics International, Ltd. • Biological products, (no disgnostic substances) • New York
Each milestone payment above shall only be made once under this Agreement upon the initial accomplishment of the relevant milestone.
